The Presence of Carboxypeptidase-M in Tumour Cells Signifies Epidermal Growth Factor Receptor Expression in Lung Adenocarcinomas: the Coexistence Predicts a Poor Prognosis Regardless of EGFR Levels

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2007 Oct 9

PMID 17922141

Citations 7

Authors

Ioannis Tsakiris

Gyorgyike Soos

Zoltan Nemes

Sandor Sz Kiss

Csilla Andras

Janos Szanto

Balazs Dezso

Affiliations

Soon will be listed here.

Abstract

Purpose: Carboxypeptidase-M (CPM) is a membrane-bound peptidase that metabolizes peptides, and is present in pneumocytes. CPM hydrolyses the C-terminal arginine of epidermal growth factor (EGF) resulting in des-Arg53-EGF which binds to the EGF receptor (EGFR) with an equal or greater affinity than native EGF. Therefore, this study focused on the possible presence of CPM in human lung adenocarcinomas (ADC) and evaluated the relationship between CPM and EGFR by assessing the impact of expressions on patient clinical outcome.

Methods: This is a retrospective study of 110 patients who underwent resection of the primary tumour (92) or metastatic tissues (18) for treatment or diagnosis. Immunohistochemistry (IHC) for CPM and EGFR was made in serial sections using standard methods.

Results: This study demonstrates for the first time that 23.6% of ADCs express carboxypeptidase-M (26/110), mainly in membrane-bound forms. The amounts and the extent of CPM within tumours vary from low levels to obviously overexpressed forms. The immunohistochemical positivity (+) for CPM in ADCs negatively correlated with disease survival. In addition, 80% of CPM+ adenocarcinomas (21/26) showed a coexpression with EGFR suggesting a high prevalence for coexistence. The follow up data indicated a significantly shorter 5-year survival time for patients with CPM+-EGFR+ (double-positive) tumours compared to those harbouring neoplasias negative for both proteins (9.5 vs. 60.4% survivals, P < 0.001).

Conclusion: The fact that CPM+ ADCs often co-express with EGFR suggests a functional-regulatory link between these proteins which might have therapeutical consequences. The present novel data could lead to improved IHC tests in lung adenocarcinomas for EGFR expression.

Citing Articles

Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer.

Stuardo-Parada A, Lopez-Munoz R, Villarroel-Espindola F, Figueroa C, Ehrenfeld P Med Oncol. 2023; 40(8):224.

PMID: 37405520 DOI: 10.1007/s12032-023-02090-x.

Genomic landscape of liposarcoma.

Kanojia D, Nagata Y, Garg M, Lee D, Sato A, Yoshida K Oncotarget. 2015; 6(40):42429-44.

PMID: 26643872 PMC: 4767443. DOI: 10.18632/oncotarget.6464.

Mapping of carboxypeptidase m in normal human kidney and renal cell carcinoma: expression in tumor-associated neovasculature and macrophages.

Denis C, Van Acker N, De Schepper S, De Bie M, Andries L, Fransen E J Histochem Cytochem. 2012; 61(3):218-35.

PMID: 23172796 PMC: 3636697. DOI: 10.1369/0022155412470456.

Carboxypeptidase-M is regulated by lipids and CSFs in macrophages and dendritic cells and expressed selectively in tissue granulomas and foam cells.

Tsakiris I, Torocsik D, Gyongyosi A, Dozsa A, Szatmari I, Szanto A Lab Invest. 2011; 92(3):345-61.

PMID: 22157720 PMC: 3290762. DOI: 10.1038/labinvest.2011.168.

Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries.

Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C Mol Cell Proteomics. 2011; 10(12):M111.010298.

PMID: 21947365 PMC: 3237079. DOI: 10.1074/mcp.M111.010298.

References

Skidgel R, Davis R, Tan F . Human carboxypeptidase M. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J Biol Chem. 1989; 264(4):2236-41. View

Skidgel R, Erdos E . Cellular carboxypeptidases. Immunol Rev. 1998; 161:129-41. DOI: 10.1111/j.1600-065x.1998.tb01577.x. View

Szatmari I, Pap A, Ruhl R, Ma J, Illarionov P, Besra G . PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006; 203(10):2351-62. PMC: 2118109. DOI: 10.1084/jem.20060141. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Reverter D, Maskos K, Tan F, Skidgel R, Bode W . Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity. J Mol Biol. 2004; 338(2):257-69. DOI: 10.1016/j.jmb.2004.02.058. View

Blanco-Aparicio C, Molina M, Frazier M, Mas J, Querol E, Aviles F . Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J Biol Chem. 1998; 273(20):12370-7. DOI: 10.1074/jbc.273.20.12370. View

Hoffman P, Mauer A, Vokes E . Lung cancer. Lancet. 2000; 355(9202):479-85. DOI: 10.1016/S0140-6736(00)82038-3. View

Pessoa L, da Silva I, Baptista H, Pesquero J, Paiva A, Bader M . Molecular structure and alternative splicing of the human carboxypeptidase M gene. Biol Chem. 2002; 383(2):263-9. DOI: 10.1515/BC.2002.028. View

Sitja-Arnau M, Molina M, Blanco-Aparicio C, Ferrer-Soler L, Lorenzo J, Aviles F . Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Lett. 2005; 226(2):169-84. DOI: 10.1016/j.canlet.2005.01.025. View

10.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M . Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1):5-26. DOI: 10.3322/canjclin.53.1.5. View

11.

Sporn M, Roberts A . Autocrine growth factors and cancer. Nature. 1985; 313(6005):745-7. DOI: 10.1038/313745a0. View

12.

Maione P, Gridelli C, Troiani T, Ciardiello F . Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006; 11(3):274-84. DOI: 10.1634/theoncologist.11-3-274. View

13.

Niemiec J, Kolodziejski L, Dyczek S . EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma. 2005; 52(3):231-7. View

14.

Li J, Rehli M, Timblin B, Tan F, Krause S, Skidgel R . Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements. Gene. 2002; 284(1-2):189-202. DOI: 10.1016/s0378-1119(01)00898-8. View

15.

Szatmari I, Gogolak P, Im J, Dezso B, Rajnavolgyi E, Nagy L . Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity. 2004; 21(1):95-106. DOI: 10.1016/j.immuni.2004.06.003. View

16.

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

17.

Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W . High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol. 2006; 59(3):255-9. PMC: 1860345. DOI: 10.1136/jcp.2005.027615. View

18.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello M . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2005; 366(1):2-16. DOI: 10.1016/j.gene.2005.10.018. View

19.

Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H . EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 2005; 118(1):180-4. DOI: 10.1002/ijc.21301. View

20.

Ferrer Soler L, Cedano J, Querol E, de Llorens R . Cloning, expression and purification of human epidermal growth factor using different expression systems. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 788(1):113-23. DOI: 10.1016/s1570-0232(02)01035-8. View